

# Christer F Aas

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5492060/publications.pdf>

Version: 2024-02-01

19  
papers

196  
citations

1040018

9  
h-index

1125717

13  
g-index

27  
all docs

27  
docs citations

27  
times ranked

96  
citing authors

#	ARTICLE	IF	CITATIONS
1	Impact of liver fibrosis and clinical characteristics on dose-adjusted serum methadone concentrations. <i>Journal of Addictive Diseases</i> , 2023, 41, 53-63.	1.3	2
2	Prevalence and correlates of suicide attempts in high-risk populations: a cross-sectional study among patients receiving opioid agonist therapy in Norway. <i>BMC Psychiatry</i> , 2022, 22, 181.	2.6	4
3	Vitamin B12 Levels, Substance Use Patterns and Clinical Characteristics among People with Severe Substance Use Disorders: A Cohort Study from Western Norway. <i>Nutrients</i> , 2022, 14, 1941.	4.1	1
4	Folate Status as a Nutritional Indicator among People with Substance Use Disorder; A Prospective Cohort Study in Norway. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 5754.	2.6	3
5	Substance use and symptoms of mental health disorders: a prospective cohort of patients with severe substance use disorders in Norway. <i>Substance Abuse Treatment, Prevention, and Policy</i> , 2021, 16, 20.	2.2	17
6	Validation of a three-item Fatigue Severity Scale for patients with substance use disorder: a cohort study from Norway for the period 2016–2020. <i>Health and Quality of Life Outcomes</i> , 2021, 19, 69.	2.4	6
7	Subjective symptoms and serum methadone concentrations: what should guide dose adjustments in methadone maintenance treatment? A naturalistic cohort study from Norway. <i>Substance Abuse Treatment, Prevention, and Policy</i> , 2021, 16, 39.	2.2	3
8	Integrated treatment of hepatitis C virus infection among people who inject drugs: A multicenter randomized controlled trial (INTRO-HCV). <i>PLoS Medicine</i> , 2021, 18, e1003653.	8.4	29
9	Changes in substance use during outpatient treatment for substance use disorders: a prospective Norwegian cohort study from 2016 to 2020. <i>Substance Abuse Treatment, Prevention, and Policy</i> , 2021, 16, 67.	2.2	3
10	Potentially addictive drugs dispensing to patients receiving opioid agonist therapy: a register-based prospective cohort study in Norway and Sweden from 2015 to 2017. <i>BMJ Open</i> , 2020, 10, e036860.	1.9	11
11	Too much or too little opioids to patients receiving opioid agonist therapy in Norway (2013–2017): a prospective cohort study. <i>BMC Health Services Research</i> , 2020, 20, 668.	2.2	5
12	On the path towards universal coverage of hepatitis C treatment among people receiving opioid agonist therapy (OAT) in Norway: a prospective cohort study from 2013 to 2017. <i>BMJ Open</i> , 2020, 10, e036355.	1.9	4
13	Health-related quality of life of long-term patients receiving opioid agonist therapy: a nested prospective cohort study in Norway. <i>Substance Abuse Treatment, Prevention, and Policy</i> , 2020, 15, 68.	2.2	26
14	Impact of clinical and sociodemographic factors on fatigue among patients with substance use disorder: a cohort study from Norway for the period 2016–2020. <i>Substance Abuse Treatment, Prevention, and Policy</i> , 2020, 15, 93.	2.2	8
15	Dispensation of attention deficit hyperactivity disorder (ADHD) medications in patients receiving opioid agonist therapy; a national prospective cohort study in Norway from 2015 to 2017. <i>BMC Psychiatry</i> , 2020, 20, 119.	2.6	12
16	Uptake and predictors of direct-acting antiviral treatment for hepatitis C among people receiving opioid agonist therapy in Sweden and Norway: a drug utilization study from 2014 to 2017. <i>Substance Abuse Treatment, Prevention, and Policy</i> , 2020, 15, 44.	2.2	10
17	Dispensations of benzodiazepines, z-hypnotics, and gabapentinoids to patients receiving opioid agonist therapy; a prospective cohort study in Norway from 2013 to 2017. <i>BMC Health Services Research</i> , 2020, 20, 352.	2.2	10
18	Integrated treatment of hepatitis C virus infection among people who inject drugs: study protocol for a randomised controlled trial (INTRO-HCV). <i>BMC Infectious Diseases</i> , 2019, 19, 943.	2.9	28

#	ARTICLE	IF	CITATIONS
19	Integrated care of severe infectious diseases to people with substance use disorders; a systematic review. <i>BMC Infectious Diseases</i> , 2019, 19, 306.	2.9	14